MedTrace Logo

Carboplatin in Treating Patients With Recurrent High-Grade Gliomas

NCT01644955 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-07-02

No results posted yet for this study

Summary

This study is being done to evaluate the toxicity and safety of carboplatin administered by convection enhanced delivery into the tumor in patients with high grade glial neoplasms. This study is a dose escalating study, (the dose of the study drug is increased at set time points). Carboplatin is in a class of drugs known as platinum-containing compounds; it slows or stops the growth of cancer cells in your body. Convection enhanced delivery involves placing one or more catheters into the brain and delivering chemotherapy through those catheters directly into the brain

Conditions

  • Adult Anaplastic Astrocytoma
  • Adult Anaplastic Oligodendroglioma
  • Recurrent Adult Brain Tumor

Interventions

DRUG

carboplatin

Carboplatin in a volume of 54 ml will be administered intracerebrally by convection enhanced delivery

PROCEDURE

Surgery

Patients will undergo surgery, which includes tumor resection and catheter placement, in the operating room.

Sponsors & Collaborators

  • James Elder

    lead OTHER

Principal Investigators

  • James Elder · Ohio State University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-11
Primary Completion
2017-12-08
Completion
2017-12-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01644955 on ClinicalTrials.gov